Second Genome is a clinical stage company with a mission to improve human health by unlocking the full potential of the microbiome. We offer the most robust approach to microbiome drug discovery and development through the deepest understanding of how the microbiome works in human health.
Second Genome's proprietary Microbiome Discovery Platform uniquely addresses current limitations in target discovery and validation by integrating world-class microbiome science with human disease biology.
We are pioneering microbiome drug discovery and development. Our lead clinical program, SGM-1019, addresses a critical unmet need in Inflammatory Bowel Disease treatment as a safe and well-tolerated oral therapy with an important disease modifying effect.